VDJ recombination is a key process in T-cell receptor (TCR) and immunoglobulin (Ig) molecules development. Comparison of ENSEMBL and GenBank database information revealed major differences in dog T-cell receptor beta (TRB) region annotations. ENSEMBL based genomic alignment of dog TRB sequence with human sequence and annotation showed a very similar structure of TRB. However, there is only one cluster of DJC segments in dogs. In dog, 38 V segments are followed by 1 D segment, 6 J segments and 1 C segment. Like humans and mice, dogs have another V segment opposite in orientation downstream of the C segment. V segments anticipated were analyzed using the RT-PCR and capillary electrophoresis. Thirty-one of them were identified in samples of thymus and spleen RNA and thus believed to be subjected to chromosomal rearrangement and RNA splicing. We identified and analyzed probable structure of canine TCR beta region, which is different when compared to sequences published in GenBank or ENSEMBL databases.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.vetimm.2009.06.001 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Identification and validation of a T cell receptor targeting KRAS G12V in HLA-A*11:01 pancreatic cancer patients.
JCI Insight
January 2025
Department of Hepatobiliary Pancreatic Surgery.
T cells targeting a KRAS mutation can induce durable tumor regression in some patients with metastatic epithelial cancer. It is unknown whether T cells targeting mutant KRAS that are capable of killing tumor cells can be identified from peripheral blood of patients with pancreatic cancer. We developed an in vitro stimulation approach and identified HLA-A*11:01-restricted KRAS G12V-reactive CD8+ T cells and HLA-DRB1*15:01-restricted KRAS G12V-reactive CD4+ T cells from peripheral blood of 2 out of 6 HLA-A*11:01-positive patients with pancreatic cancer whose tumors expressed KRAS G12V.
View Article and Find Full Text PDFPseudoprogression in CAR-T cell therapy for solid tumor: Case report.
Front Immunol
January 2025
Biotherapy Center & Cancer Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
We reported the pseudoprogression in an elderly patient with advanced gastric cancer after chimeric antigen receptor (CAR)-T cell therapy. The hepatic metastases enlarged 1 month after CAR-T cell infusion and then shrunk the next month as seen through computed tomography scanning. Based on a comprehensive evaluation that includes imaging, pathology, serum tumor markers, and clinical symptoms, we arrived at a diagnosis of pseudoprogression after CAR-T cell therapy, which has not been reported in previous studies.
View Article and Find Full Text PDFAdvancements and Future Directions of Dual-Target Chimeric Antigen Receptor T-Cell Therapy in Preclinical and Clinical Studies.
J Immunol Res
January 2025
Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
In recent years, chimeric antigen receptor T-cell (CAR-T) therapy has made groundbreaking progress in the treatment of various cancer types, particularly hematological malignancies. In the meantime, various preclinical and clinical studies have extensively explored dual-target CAR-T therapies which can be designed to recognize two antigens simultaneously based on the immunophenotype of tumor cells. Compared with single-target CAR-T approach, dual-target CAR-T therapies demonstrate varying degrees of superior antitumor CAR effects, prevent antigen escape and relapse, reduce on-target off-tumor effects, and ensure durable responses in different types of cancer.
View Article and Find Full Text PDFPresence of minimal residual disease determined by next-generation sequencing is not a reliable prognostic biomarker in children with acute lymphoblastic leukemia.
Leuk Lymphoma
January 2025
Faculty of Pharmacy, Center for Biomolecular Pharmaceutical Analyses, University Ss. Cyril and Methodius in Skopje, Skopje, North Macedonia.
The role of next-generation sequencing (NGS) for minimal residual disease (MRD) assessment in pediatric acute lymphoblastic leukemia (ALL) is still under consideration. Fifty pediatric patients were prospectively evaluated for specific clonal rearrangements of immunoglobulin and T-cell receptor genes using NGS analysis at diagnosis and on days 33 and 78 from therapy onset. The prognostic value or the NGS-MRD status was analyzed after a median follow-up of 4 years.
View Article and Find Full Text PDFApplication of adoptive cell therapy in malignant melanoma.
J Transl Med
January 2025
Department of Plastic and Reconstructive Surgery, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, 200032, People's Republic of China.
Cutaneous melanoma is one of the most aggressive skin cancers originating from skin pigment cells. Patients with advanced melanoma suffer a poor prognosis and generally cannot benefit well from surgical resection and chemo/target therapy due to metastasis and drug resistance. Thus, adoptive cell therapy (ACT), employing immune cells with specific tumor-recognizing receptors, has emerged as a promising therapeutic approach to display on-tumor toxicity.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!